Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Impact · against what's priced in

Rani Therapeutics (RANI) sees a significant catalyst from Phase 1A data showing over 150% relative bioavailability for its oral obesity candidate, validating its delivery platform. The expansion of the Chugai partnership and the shift toward a platform licensing model further reduce operational risk while enhancing technical credibility. For partners Chugai and Celltrion, the news provides incremental validation of their respective molecules and biosimilars in an oral format.

RANI+0.80

No priced-in read yet